
Our team is focused on developing and delivering the first oral drug for eosinophilic asthma
Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners,
whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.
Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners, whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.
Company Leaders

Jorge Bartolome
Chief Executive Officer

Peter Wijngaard, Ph.D.
Chief Development Officer

Calman Prussin, M.D.
Chief Scientific Officer

Mark Kreston
Chief Commercial Officer

Christopher Courts, CPA
Chief Financial Officer

Eric Bradford, M.D.
Chief Medical Officer

Robin Walker, J.D.
Chief Legal Officer and Corporate Secretary

Andrew Friedman
PharmD – Executive Vice President, Head of Global Regulatory and Development Strategy

Dan Tokich
Head of Global Supply

Lex Kay
Head of Global Quality

Richard Fires
Head of Human Resources
Board of Directors

Jorge Bartolome
Chief Executive Officer, areteia therapeutics

Dan Becker, M.D., Ph.D.
Managing Director, Access Biotechnology

Paul Berns
Managing Director, Arch Venture Partners

Michael Bozik, M.D.
President, Biohaven Labs
Former Chief Executive Officer, Knopp Biosciences, LLC

Steve Butts
Chief Executive Officer, Arrivo BioVentures, LLC

Benjamin Gomez
Managing Director, Pilot House Associates

Don Hayden
Chair of the Board, areteia therapeutics

Adam Koppel, M.D., Ph.D.
Partner, Bain Capital

Ian Smith
Interim Chief Executive Officer, Stoke Therapeutics

Elyse Stock, M.D.
Senior Scientific Advisor, Biohaven Pharmaceuticals